Defining level A IVIVC dissolution specifications based on individual in vitro dissolution profiles of a controlled release formulation

Publication date: 1 July 2018
Source:European Journal of Pharmaceutical Sciences, Volume 119
Author(s): I. González-García, A. García-Arieta, M. Merino-Sanjuan, V. Mangas-Sanjuan, M. Bermejo
Regulatory guidelines recommend that, when a level A IVIVC is established, dissolution specification should be established using averaged data and the maximum difference between AUC and Cmax between the reference and test formulations cannot be greater than 20%. However, averaging data assumes a loss of information and may reflect a bias in the results. The objective of the current work is to present a new approach to establish dissolution specifications using a new methodology (individual approach) instead of average data (classical approach). Different scenarios were established based on the relationship between in vitro-in vivo dissolution rate coefficient using a level A IVIVC of a controlled release formulation. Then, in order to compare this new approach with the classical one, six additional batches were simulated. For each batch, 1000 simulations of a dissolution assay were run. Cmax ratios between the reference formulation and each batch were calculated showing that the individual approach was more sensitive and able to detect differences between the reference and the batch formulation compared to the classical approach. Additionally, the new methodology displays wider dissolution specification limits than the classical approach, ensuring that any tablet from the new batch would generate in vivo profiles which its AUC or Cmax ratio will be out of the 0.8–1.25 range, taking into account the in vitro and in vivo variability of the new batches developed.

Graphical abstract

https://ift.tt/2HHM4sy